BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 14980540)

  • 1. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.
    Marcucci F; Lefoulon F
    Drug Discov Today; 2004 Mar; 9(5):219-28. PubMed ID: 14980540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive and active drug targeting: drug delivery to tumors as an example.
    Torchilin VP
    Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
    Greco F; Vicent MJ
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers.
    Saul JM; Annapragada AV; Bellamkonda RV
    J Control Release; 2006 Sep; 114(3):277-87. PubMed ID: 16904220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does a targeting ligand influence nanoparticle tumor localization or uptake?
    Pirollo KF; Chang EH
    Trends Biotechnol; 2008 Oct; 26(10):552-8. PubMed ID: 18722682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy.
    Wagner E; Kircheis R; Walker GF
    Biomed Pharmacother; 2004 Apr; 58(3):152-61. PubMed ID: 15082337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
    Talekar M; Kendall J; Denny W; Garg S
    Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
    Hamad I; Moghimi SM
    Expert Opin Drug Deliv; 2008 Feb; 5(2):205-19. PubMed ID: 18248319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
    Sultana S; Khan MR; Kumar M; Kumar S; Ali M
    J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
    Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
    J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
    Gopin A; Pessah N; Shamis M; Rader C; Shabat D
    Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
    [No Abstract]   [Full Text] [Related]  

  • 18. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
    Danhier F; Feron O; Préat V
    J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting.
    Murakami M; Cabral H; Matsumoto Y; Wu S; Kano MR; Yamori T; Nishiyama N; Kataoka K
    Sci Transl Med; 2011 Jan; 3(64):64ra2. PubMed ID: 21209412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer-protein and polymer-drug conjugates in cancer therapy.
    Thanou M; Duncan R
    Curr Opin Investig Drugs; 2003 Jun; 4(6):701-9. PubMed ID: 12901229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.